2 g), so patients can take as few as two tablets once daily
The Multi MatriX system (MMX®) formulation of mesalazine (Lialda®; Mesavancol®; Mezavant®) [henceforth referred to as MMX mesalazine] is an oral, high
Medical Device Technology & Business
Mesalamine with MMX Multi Matrix System® technology (hereafter referred to as MMX mesalamine) is an oral, high-strength (1
Indeed, in the last few years, MMX® technology has been widely used in the development of various drugs for the treatment of inflammatory and infectious gastrointestinal diseases localized in the colon
Mesalamine with MMX Multi Matrix System technology (hereafter referred to as MMX mesalamine) is an oral, high-strength (1
, Wayne, PA, under license from Giuliani SpA, Milan, Italy) is a novel, once-daily, high-strength (1
0, the core reveals a hydrophilic matrix that turns into a Novel technology has resulted in the development and FDA-approval of a multi-matrix release (MMX) mesalamine
2 g per tablet) formulation of 5-ASA designed to be administered once daily (QD)
2 g/tablet) formulation of mesalamine, utilizing MMX Multi Matrix System (MMX) technology designed to deliver
Additionally, it attributes for targeting strategy aimed at the colon and offers modified prolonged drug release
Background Two phase III studies have evaluated mesalazine (mesalamine) with MMX (Multi Matrix System) technology in patients with active mild-to-moderate ulcerative colitis
Mesalamine may cause serious side effects
We performed a randomized, double-blind, parallel-group, placebo-controlled, multicenter phase III study in patients with mild to moderately Oral mesalazine (also known as mesalamine) is a 5-aminosalicylic acid compound used in the treatment of mild to moderate ulcerative colitis, with high rates of efficacy in induction and maintenance of remission
MMX technology, which allows a reduction in the number of pills to be taken and daily administrations, may facilitate adherence to treatment and carry further clinical benefits
MMX® technology is, thus, A second trial compared three different MMX® mesalamine doses (1